Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven”) announced today the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase (MPO)...
Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically...
– ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for antibody drug conjugate (ADC) development – Phase I dose escalation and expansion trial will evaluate ADCT-601 in 75 cancer patients – ADCT-601 is...
The Center for Beta Cell Therapy in Diabetes, coordinator of an international consortium in translational medicine in diabetes, and ViaCyte, Inc., a privately held regenerative medicine company, today announced that a human stem cell-derived product candidate has been...
ImaginAb, Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of ImaginAb’s CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the...
Email
Text